



Product portfolio

GLAUCOMA

RETINAL DISEASE

FLOATERS (VITREOUS OPACITIES)

DIAGNOSTIC ULTRASOUND

Helping the world see clearly

Discover, develop and deliver

Ellex works with leading physicians, technical institutions and universities to discover, develop and deliver new ways to treat of some of the world's most prevalent eye conditions.

Over 35,000 Ellex ophthalmic laser and ultrasound systems are in use in more than 100 countries around the world, achieving ophthalmic outcomes once never thought possible – safely, effectively, accurately and consistently. Initially with SLT Selective Light Therapy, then through the introduction of iTrack™ – our solution for minimally invasive glaucoma surgery (MIGS) – and more recently with 2RT® Retinal Rejuvenation Therapy, we're expanding our focus on the development of restorative, rejuvenative treatment options that work holistically with the body's natural healing ability.



tango
reflex

Offset μm



Posterior



Anterior

ellex

Glaucoma

Tango™ and Tango Reflex™ for Selective Light Therapy

Non-thermal nanosecond Selective Light Therapy (SLT) reduces IOP as effectively as medication^{*1}

Determine potential point(s) of glaucoma blockage and deliver treatment – consistently and safely

Sharp edged aiming beam, three shots per second firing rate

Tango Reflex™ also offers laser-based floater treatment functionality for maximum versatility

^{*} when used as a first-line therapy

¹ Katz LJ, Steinmann WC, Kabir A, Molineaux J, Wizov SS, Marcellino G; SLT/Med Study Group. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. *J Glaucoma*. 2012;21:460-8

iTrack™ Surgical System for ABiC™ and Canaloplasty

ABiC™ – the optimum in minimally invasive glaucoma surgery

iTrack™ restores the eye's outflow pathways – naturally, safely, and efficaciously

Addresses all outflow pathway resistance points, including blockages in the collector channel ostia – atraumatically

Efficacious in a wide spectrum of patients, including phakic and pseudophakic patients, and in cases of controlled and uncontrolled glaucoma

Can be performed as a standalone procedure, or as an adjunct to other treatments, including MIGS and SLT

Average 30% reduction in mean IOP and average 50% reduction in medication dependence²

Canaloplasty – the restorative surgery for later stages of glaucoma

iTrack™ achieves same reduction in IOP as trabeculectomy but with better safety^{3, 4}

Obviates bleb formation – improving and simplifying postoperative care

Extensive peer review data – safe, efficacious, proven minimally invasive

² 228-eye ABiC 12-Month Case Series Data, presented at ASCRS 2016. Data on file. Ellex Medical.

³ Lewis RA, von Wolff K, Tetz M, et al. Canaloplasty: three-year results of circumferential viscodilation and tensioning of Schlemm's canal using a microcatheter to treat open-angle glaucoma. *J Cataract Refract. Surg.* 2011(37):682-690.

⁴ Bull H, von Wolff K, Korger N, Tetz M. Three-year canaloplasty outcomes for the treatment of open-angle glaucoma: European study results. *Graefes Arch*



Helping physicians
to prioritize
proactive care



iTrack SURGICAL
SYSTEM™

tango reflex™



tango™

Floater management

Ultra Q Reflex™ and Tango Reflex™ for Laser Floater Treatment

Reflex Technology™ at the heart of
our floater treatment solutions

True Coaxial Illumination – TCI™


Converges and focuses sight line,
target illumination and treatment
beam into one optical path

Optimizes visualization and
illumination of the vitreous

Effortlessly switch between on-axis
and off-axis modes for improved
visualization and treatment



LFT, Ellex: pre-treatment



LFT, Ellex: post-treatment



Transform visual
functionality, improve
patients' life quality

tango reflex™



ultra Q reflex™



Retinal disease

Integre Pro™ and Integre Pro Scan™ for photocoagulation

True Spot™ technology for better visualization and optimal illumination

Eliminate hotspots, achieve optimal, homogenous lesions

Real-time, active light feedback continuously monitors and adjusts power output

Maximize treatment consistency and efficacy across wide range of pathologies

Enhanced depth perception and wider peripheral view

High power yellow-red configuration redefines multi-color laser technology

Also available with Integre Pro Scan™ configuration

Intuitive tablet user interface for easy, accurate and precise pattern spacing, shaping and positioning

Perform PRP 100% faster than with conventional single-spot photocoagulation*

Comprehensive pattern and wavelength choice to cover all retina pathologies

Speed up procedures with computer-controlled pattern generation

2RT® for Retinal Rejuvenation Therapy

Proprietary Nanopix Technology™ combines an ultra-short nanosecond laser pulse and a unique pixelated beam profile to target selected individual cells within RPE in order to stimulate the eye's natural healing mechanism

Slows degenerative processes that cause retinal disease¹

Induces mononuclear cell response including microglia stimulation¹

Uses around 500 times less energy than retinal photocoagulation²

* Data on file

¹ Jobling et al., "Nanosecond Laser Therapy Reverses Pathologic and Molecular Changes in Age-Related Macular Degeneration without Retinal Damage," *The FASEB Journal* 29, no. 2 (February 1, 2015): 696–710, doi:10.1096/fj.14-262444.

² Casson RJ. Et al., "Pilot randomized trial of a nanopulse retinal laser versus conventional photocoagulation for the treatment of diabetic macular oedema", *Clin Experiment Ophthalmol.* 2012 Aug;40(6):604-10

2RT

nanopix
TECHNOLOGY™



Precision and
efficiency for optimized
treatment outcomes

integre pro scan™



Diagnostic ultrasound

Eye One™ and Eye Cubed™ for ultrasound examination, measurement and diagnosis

Comprehensive ultrasound
solutions for posterior and
anterior segments

Customizable configuration:


- B-Scan, 40 MHz UBM;
 - B-Scan, 10 MHz Posterior;
 - A-Scan, Biometry;
 - A-Scan, Standardized
Diagnostic
-

Advanced movie
mode technology


Real-time image capture

Wide range of measurement
and annotation tools and
reporting capabilities


Intuitive, easy-to-use
software




Posterior Vitreous Detachment, PVD
B-Scan 10 MHz



Melanoma
B-Scan 10 MHz



Pediatric Cataract
B-Scan 40 MHz



Hyphema with bowing of iris
B-Scan 40 MHz



Intuitive, high
performance
solutions

eye cubed™



eye one™



Find out more...



Contact us now to schedule a demonstration

Head Office

3 Second Avenue
Mawson Lakes, SA, 5095 AUSTRALIA
+61 8 7074 8200

Ellex Inc. (USA)

7138 Shady Oak Road
Minneapolis, MN, 55344 USA
800 824 7444

Ellex Deutschland GmbH

ZPO floor 1, Carl-Scheele-Str.16
12489 Berlin GERMANY
+49 30 6392896 00

Ellex Inc. (Japan)

Harumi Center Bldg 5F, 2-5-24 Harumi Chuo-ku
Tokyo 104-0053 JAPAN
+81 3 5859 0470

Registered Office

82 Gilbert Street
Adelaide, SA, 5000 AUSTRALIA
+61 8 7074 8200

Ellex iTrack

41316 Christy Street
Fremont, CA, 94538 USA
800 391 2316

Ellex France SARL

La Chaufferie – 555 chemin du bois
69140 Rillieux la Pape FRANCE
+33 4 8291 0460

Ellex Australia

3 Second Avenue
Mawson Lakes, SA, 5095 AUSTRALIA
+61 8 7074 8200

Helping the world see clearly

Ellex is the manufacturer of 2RT®. It has been approved for the indications Clinically Significant Macular Edema (CSME) and in patients with early Age-Related Macular Degeneration (AMD) where it can produce bilateral improvements in macular appearance and function under CE marking. Ellex does not accept any responsibility for use of the system outside of these indications. 2RT® has a CE Mark (Conformité Européenne) for treatment in patients with early AMD where it can produce bilateral improvements in macular appearance and function. 2RT® has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) 510(k) Market clearance for the treatment of Clinically Significant Macula Edema (CSME).

Integre Pro Scan™ has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) 510(k) Market release for the indications of Retinal Photocoagulation, Laser Trabeculoplasty and Laser Iridotomy.

Integre Pro™ has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) 510(k) Market release for the indications of Retinal Photocoagulation, Laser Trabeculoplasty and Laser Iridotomy.

Ellex is the manufacturer of Reflex Technology for use in the treatment of symptomatic floater patients. It has been approved for the indication of Posterior Membranectomy (incl. Nd:YAG Laser Vitreolysis/Laser Floater Treatment) whereby it may potentially improve the patient's perception of visual functionality. Ellex does not accept any responsibility for use of the system outside of these indications.

Ultra Q Reflex™ has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) 510(k) Market release for the indications of Posterior Membranectomy (incl. Nd:YAG Laser Vitreolysis/Laser Floater Treatment), Capsulotomy and Laser Iridotomy.

Tango Reflex™ has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) 510(k) Market release for the indications of Posterior Membranectomy (incl. Nd:YAG Laser Vitreolysis/Laser Floater Treatment), Selective Laser Trabeculoplasty (Selective Light Therapy, SLT) Capsulotomy and Laser Iridotomy.

Ultra Q™ has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) 510(k) Market release for the indications of Capsulotomy and Laser Iridotomy

Tango™ has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) 510(k) Market release for the indications of Selective Laser Trabeculoplasty (Selective Light Therapy, SLT) Capsulotomy and Laser Iridotomy.

Ellex is the manufacturer of the iTrack Canaloplasty microcatheter for the reduction of intraocular pressure (IOP) in adult patients with open-angle glaucoma. It has been approved for the indication of fluid infusion and aspiration during surgery, and for catheterization and viscodilation of Schlemm's canal during the Canaloplasty procedure. Ellex does not accept any responsibility for use of the iTrack Canaloplasty microcatheter outside of these indications. iTrack™ has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) 510(k) # K080067 for the treatment of open-angle glaucoma.